RxDoctor Payments Data

Ronnie Oommen, MD

Hospitalist · Albany, NYNPI 1548581887

Payments from drug & device makers

$1,413in general payments, 2019–2025

Across 14 payments — averaging $100.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$245
  • Boehringer Ingelheim$227
  • Lilly USA, LLC$187
  • AstraZeneca$123
  • Sanofi-aventis U.S. LLC$119
  • Johnson & Johnson$118
  • plus $395 from 4 others

What the payments were for

  • Food & beverage$1,413100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,413 in reported general payments places this provider in the 90th percentile of 1,860 hospitalist providers in New York.

See all hospitalist providers in New York

Medicare billing

Part B allowed, 2024
$20,911
Medicare patients
100
Services billed
168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$45,742
EliquisApixaban59$30,897
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$14,901
LinzessLinaclotide14$7,815
XareltoRivaroxaban14$7,276
Rosuvastatin Calcium97$7,102
Fluticasone-VilanterolFluticasone/Vilanterol18$6,746
Atorvastatin Calcium139$6,599
DapagliflozinDapagliflozin Propanediol13$6,385
Insulin Aspart FlexpenInsulin Aspart32$5,422
Pregabalin44$4,461
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$4,378
Duloxetine Hcl57$4,302
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$4,285
Ondansetron Hcl18$4,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$118$7,27614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,860 hospitalist providers in New York.

Other hospitalist in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →